RxDoctor Payments Data

Lauren Johnson

Nurse Practitioner · Crofton, KYNPI 1144992884

Payments from drug & device makers

$1,642in general payments, 2019–2025

Across 28 payments — averaging $58.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$685
  • Lilly USA, LLC$372
  • Sumitomo Pharma America, Inc.$125
  • Neurocrine Biosciences, Inc.$78
  • Avadel CNS Pharmaceuticals, LLC$73
  • Amgen$68
  • plus $242 from 8 others

What the payments were for

  • Food & beverage$1,642100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,642 in reported general payments places this provider in the 75th percentile of 1,918 nurse practitioner providers in Kentucky.

See all nurse practitioner providers in Kentucky

Medicare billing

Part B allowed, 2024
$1,540
Medicare patients
24
Services billed
63

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JanuviaSitagliptin Phosphate22$13,484
JardianceEmpagliflozin15$10,663
XareltoRivaroxaban14$8,260
Trelegy ElliptaFluticasone/Umeclidin/Vilanter12$8,171
Janumet XrSitagliptin Phos/Metformin Hcl11$6,529
Rosuvastatin Calcium30$2,772
Fluticasone Propionate84$2,264
Atorvastatin Calcium81$1,060
Quetiapine Fumarate21$1,043
Levothyroxine Sodium85$1,028
Ventolin HfaAlbuterol Sulfate15$900
Montelukast Sodium29$529
Omeprazole66$524
Famotidine27$501
FenofibrateFenofibrate Nanocrystallized16$452

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MerckJanuvia, Janumet Xr$16$20,01233 claims
Boehringer IngelheimJardiance$17$10,66315 claims
GSKTrelegy Ellipta$23$8,17112 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,918 nurse practitioner providers in Kentucky.

Other nurse practitioner in Crofton

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →